A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

Exclusion Criteria

• •Suspected or known pulmonary veno-occlusive disease
• •Known allergies, hypersensitivity, or intolerance to selexipag or its excipients
• •Interruption of study intervention for more than 14 days since the last dose of study intervention taken in the parent study
• •Female participant being pregnant, or breastfeeding, or planning to become pregnant at the time of screening and while enrolled in this study
• •Uncontrolled thyroid disease
• •Known and documented severe hepatic impairment, example, Child-Pugh Class C
• •Taken any disallowed therapies, Concomitant Therapy before the planned first dose of study intervention: a) treatment with a strong CYP 2C8 inhibitor (example, gemfibrozil); b) treatment with oral prostacyclin analogs (example, beraprost, treprostinil) since the last dose of study intervention taken in the parent study; c) any investigational treatment other than selexipag
• •Severe coronary heart disease or unstable angina, myocardial infarction within the last 6 months, decompensated cardiac failure if not under close medical supervision, severe arrhythmia, cerebrovascular events (example, transient ischemic attack, stroke) within the last 3 months, or congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to PH